The estimated disease burden of acute COVID-19 in the Netherlands in 2020, in disability-adjusted life-years
The impact of COVID-19 on population health is recognised as being substantial, yet few studies have attempted to quantify to what extent infection causes mild or moderate symptoms only, requires hospital and/or ICU admission, results in prolonged and chronic illness, or leads to premature death. We...
Gespeichert in:
| Veröffentlicht in: | European journal of epidemiology 2022-10, Vol.37 (10), p.1035-1047 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1047 |
|---|---|
| container_issue | 10 |
| container_start_page | 1035 |
| container_title | European journal of epidemiology |
| container_volume | 37 |
| creator | McDonald, Scott A. Lagerweij, Giske R. de Boer, Pieter de Melker, Hester E. Pijnacker, Roan Mughini Gras, Lapo Kretzschmar, Mirjam E. den Hartog, Gerco van Gageldonk-Lafeber, Arianne B. van den f, Susan Wallinga, Jacco |
| description | The impact of COVID-19 on population health is recognised as being substantial, yet few studies have attempted to quantify to what extent infection causes mild or moderate symptoms only, requires hospital and/or ICU admission, results in prolonged and chronic illness, or leads to premature death. We aimed to quantify the total disease burden of acute COVID-19 in the Netherlands in 2020 using the disability-adjusted life-years (DALY) measure, and to investigate how burden varies between age-groups and occupations. Using standard methods and diverse data sources (mandatory notifications, population-level seroprevalence, hospital and ICU admissions, registered COVID-19 deaths, and the literature), we estimated years of life lost (YLL), years lived with disability, DALY and DALY per 100,000 population due to COVID-19, excluding post-acute sequelae, stratified by 5-year age-group and occupation category. The total disease burden due to acute COVID-19 was 286,100 (95% CI: 281,700–290,500) DALY, and the per-capita burden was 1640 (95% CI: 1620–1670) DALY/100,000, of which 99.4% consisted of YLL. The per-capita burden increased steeply with age, starting from 60 to 64 years, with relatively little burden estimated for persons under 50 years old. SARS-CoV-2 infection and associated premature mortality was responsible for a considerable direct health burden in the Netherlands, despite extensive public health measures. DALY were much higher than for other high-burden infectious diseases, but lower than estimated for coronary heart disease. These findings are valuable for informing public health decision-makers regarding the expected COVID-19 health burden among population subgroups, and the possible gains from targeted preventative interventions. |
| doi_str_mv | 10.1007/s10654-022-00895-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9366822</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2701139283</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-ff252c7d5de9831a7b37f948d9507ca8a10c127b61ea526036ad6d05389f43953</originalsourceid><addsrcrecordid>eNp9kUtv3CAUhVGVKpmm_QNdRJay6aKkFzCvTaRq-ooUNZu0W4TNdcLIYydgV5p_XyaT5rXoBhD3u4d7OIS8Z3DCAPSnzEDJmgLnFMBYSeEVWTCpBdXc1HtkAcIKyq2FA_Im5xUUCqzcJwdCWsm4NgvSX15jhXmKaz9hqELM6DNWzZwCDtXYVb6dJ6yWF7_PvlBmqzhUU-n4iWVNvR9C3l5x4PBxeyj9vol9nDbUh9Wct5p97JBu0Kf8lrzufJ_x3f1-SH59-3q5_EHPL76fLT-f07bW9US7jkve6iADWiOY143Qna1NsBJ0641n0JbpG8XQS65AKB9UACmM7WphpTgkpzvdm7lZY2hxmJLv3U0qLtPGjT6655UhXrur8Y-zQinDeRH4cC-Qxtu5fI9bx9xiXwzjOGfHNTAmLDeioMcv0NU4p6HYK5Rg3BipVKH4jmrTmHPC7mEYBm4bptuF6UqY7i5MB6Xp6KmNh5Z_6RVA7IBcSsMVpse3_yP7F7VwqO4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2731288566</pqid></control><display><type>article</type><title>The estimated disease burden of acute COVID-19 in the Netherlands in 2020, in disability-adjusted life-years</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>McDonald, Scott A. ; Lagerweij, Giske R. ; de Boer, Pieter ; de Melker, Hester E. ; Pijnacker, Roan ; Mughini Gras, Lapo ; Kretzschmar, Mirjam E. ; den Hartog, Gerco ; van Gageldonk-Lafeber, Arianne B. ; van den f, Susan ; Wallinga, Jacco</creator><creatorcontrib>McDonald, Scott A. ; Lagerweij, Giske R. ; de Boer, Pieter ; de Melker, Hester E. ; Pijnacker, Roan ; Mughini Gras, Lapo ; Kretzschmar, Mirjam E. ; den Hartog, Gerco ; van Gageldonk-Lafeber, Arianne B. ; van den f, Susan ; Wallinga, Jacco ; RIVM COVID-19 surveillance, epidemiology team</creatorcontrib><description>The impact of COVID-19 on population health is recognised as being substantial, yet few studies have attempted to quantify to what extent infection causes mild or moderate symptoms only, requires hospital and/or ICU admission, results in prolonged and chronic illness, or leads to premature death. We aimed to quantify the total disease burden of acute COVID-19 in the Netherlands in 2020 using the disability-adjusted life-years (DALY) measure, and to investigate how burden varies between age-groups and occupations. Using standard methods and diverse data sources (mandatory notifications, population-level seroprevalence, hospital and ICU admissions, registered COVID-19 deaths, and the literature), we estimated years of life lost (YLL), years lived with disability, DALY and DALY per 100,000 population due to COVID-19, excluding post-acute sequelae, stratified by 5-year age-group and occupation category. The total disease burden due to acute COVID-19 was 286,100 (95% CI: 281,700–290,500) DALY, and the per-capita burden was 1640 (95% CI: 1620–1670) DALY/100,000, of which 99.4% consisted of YLL. The per-capita burden increased steeply with age, starting from 60 to 64 years, with relatively little burden estimated for persons under 50 years old. SARS-CoV-2 infection and associated premature mortality was responsible for a considerable direct health burden in the Netherlands, despite extensive public health measures. DALY were much higher than for other high-burden infectious diseases, but lower than estimated for coronary heart disease. These findings are valuable for informing public health decision-makers regarding the expected COVID-19 health burden among population subgroups, and the possible gains from targeted preventative interventions.</description><identifier>ISSN: 0393-2990</identifier><identifier>ISSN: 1573-7284</identifier><identifier>EISSN: 1573-7284</identifier><identifier>DOI: 10.1007/s10654-022-00895-0</identifier><identifier>PMID: 35951278</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Age ; Cardiology ; Cardiovascular disease ; Cardiovascular diseases ; Complications ; Coronary artery disease ; Coronaviruses ; Cost of Illness ; COVID-19 ; Decision making ; Disability-Adjusted Life Years ; Disabled Persons ; Epidemiology ; Heart diseases ; Humans ; Infectious Diseases ; Medicine ; Medicine & Public Health ; Middle Aged ; Netherlands - epidemiology ; Oncology ; Population ; Public Health ; Quality-Adjusted Life Years ; SARS-CoV-2 ; Seroepidemiologic Studies ; Serology ; Severe acute respiratory syndrome coronavirus 2 ; Signs and symptoms ; Subgroups ; Viral diseases</subject><ispartof>European journal of epidemiology, 2022-10, Vol.37 (10), p.1035-1047</ispartof><rights>The Author(s) 2022</rights><rights>2022. The Author(s).</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-ff252c7d5de9831a7b37f948d9507ca8a10c127b61ea526036ad6d05389f43953</citedby><cites>FETCH-LOGICAL-c474t-ff252c7d5de9831a7b37f948d9507ca8a10c127b61ea526036ad6d05389f43953</cites><orcidid>0000-0003-0788-6011</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10654-022-00895-0$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10654-022-00895-0$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35951278$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McDonald, Scott A.</creatorcontrib><creatorcontrib>Lagerweij, Giske R.</creatorcontrib><creatorcontrib>de Boer, Pieter</creatorcontrib><creatorcontrib>de Melker, Hester E.</creatorcontrib><creatorcontrib>Pijnacker, Roan</creatorcontrib><creatorcontrib>Mughini Gras, Lapo</creatorcontrib><creatorcontrib>Kretzschmar, Mirjam E.</creatorcontrib><creatorcontrib>den Hartog, Gerco</creatorcontrib><creatorcontrib>van Gageldonk-Lafeber, Arianne B.</creatorcontrib><creatorcontrib>van den f, Susan</creatorcontrib><creatorcontrib>Wallinga, Jacco</creatorcontrib><creatorcontrib>RIVM COVID-19 surveillance, epidemiology team</creatorcontrib><title>The estimated disease burden of acute COVID-19 in the Netherlands in 2020, in disability-adjusted life-years</title><title>European journal of epidemiology</title><addtitle>Eur J Epidemiol</addtitle><addtitle>Eur J Epidemiol</addtitle><description>The impact of COVID-19 on population health is recognised as being substantial, yet few studies have attempted to quantify to what extent infection causes mild or moderate symptoms only, requires hospital and/or ICU admission, results in prolonged and chronic illness, or leads to premature death. We aimed to quantify the total disease burden of acute COVID-19 in the Netherlands in 2020 using the disability-adjusted life-years (DALY) measure, and to investigate how burden varies between age-groups and occupations. Using standard methods and diverse data sources (mandatory notifications, population-level seroprevalence, hospital and ICU admissions, registered COVID-19 deaths, and the literature), we estimated years of life lost (YLL), years lived with disability, DALY and DALY per 100,000 population due to COVID-19, excluding post-acute sequelae, stratified by 5-year age-group and occupation category. The total disease burden due to acute COVID-19 was 286,100 (95% CI: 281,700–290,500) DALY, and the per-capita burden was 1640 (95% CI: 1620–1670) DALY/100,000, of which 99.4% consisted of YLL. The per-capita burden increased steeply with age, starting from 60 to 64 years, with relatively little burden estimated for persons under 50 years old. SARS-CoV-2 infection and associated premature mortality was responsible for a considerable direct health burden in the Netherlands, despite extensive public health measures. DALY were much higher than for other high-burden infectious diseases, but lower than estimated for coronary heart disease. These findings are valuable for informing public health decision-makers regarding the expected COVID-19 health burden among population subgroups, and the possible gains from targeted preventative interventions.</description><subject>Age</subject><subject>Cardiology</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Complications</subject><subject>Coronary artery disease</subject><subject>Coronaviruses</subject><subject>Cost of Illness</subject><subject>COVID-19</subject><subject>Decision making</subject><subject>Disability-Adjusted Life Years</subject><subject>Disabled Persons</subject><subject>Epidemiology</subject><subject>Heart diseases</subject><subject>Humans</subject><subject>Infectious Diseases</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Netherlands - epidemiology</subject><subject>Oncology</subject><subject>Population</subject><subject>Public Health</subject><subject>Quality-Adjusted Life Years</subject><subject>SARS-CoV-2</subject><subject>Seroepidemiologic Studies</subject><subject>Serology</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Signs and symptoms</subject><subject>Subgroups</subject><subject>Viral diseases</subject><issn>0393-2990</issn><issn>1573-7284</issn><issn>1573-7284</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kUtv3CAUhVGVKpmm_QNdRJay6aKkFzCvTaRq-ooUNZu0W4TNdcLIYydgV5p_XyaT5rXoBhD3u4d7OIS8Z3DCAPSnzEDJmgLnFMBYSeEVWTCpBdXc1HtkAcIKyq2FA_Im5xUUCqzcJwdCWsm4NgvSX15jhXmKaz9hqELM6DNWzZwCDtXYVb6dJ6yWF7_PvlBmqzhUU-n4iWVNvR9C3l5x4PBxeyj9vol9nDbUh9Wct5p97JBu0Kf8lrzufJ_x3f1-SH59-3q5_EHPL76fLT-f07bW9US7jkve6iADWiOY143Qna1NsBJ0641n0JbpG8XQS65AKB9UACmM7WphpTgkpzvdm7lZY2hxmJLv3U0qLtPGjT6655UhXrur8Y-zQinDeRH4cC-Qxtu5fI9bx9xiXwzjOGfHNTAmLDeioMcv0NU4p6HYK5Rg3BipVKH4jmrTmHPC7mEYBm4bptuF6UqY7i5MB6Xp6KmNh5Z_6RVA7IBcSsMVpse3_yP7F7VwqO4</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>McDonald, Scott A.</creator><creator>Lagerweij, Giske R.</creator><creator>de Boer, Pieter</creator><creator>de Melker, Hester E.</creator><creator>Pijnacker, Roan</creator><creator>Mughini Gras, Lapo</creator><creator>Kretzschmar, Mirjam E.</creator><creator>den Hartog, Gerco</creator><creator>van Gageldonk-Lafeber, Arianne B.</creator><creator>van den f, Susan</creator><creator>Wallinga, Jacco</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T2</scope><scope>7TK</scope><scope>7TS</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0788-6011</orcidid></search><sort><creationdate>20221001</creationdate><title>The estimated disease burden of acute COVID-19 in the Netherlands in 2020, in disability-adjusted life-years</title><author>McDonald, Scott A. ; Lagerweij, Giske R. ; de Boer, Pieter ; de Melker, Hester E. ; Pijnacker, Roan ; Mughini Gras, Lapo ; Kretzschmar, Mirjam E. ; den Hartog, Gerco ; van Gageldonk-Lafeber, Arianne B. ; van den f, Susan ; Wallinga, Jacco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-ff252c7d5de9831a7b37f948d9507ca8a10c127b61ea526036ad6d05389f43953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Age</topic><topic>Cardiology</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Complications</topic><topic>Coronary artery disease</topic><topic>Coronaviruses</topic><topic>Cost of Illness</topic><topic>COVID-19</topic><topic>Decision making</topic><topic>Disability-Adjusted Life Years</topic><topic>Disabled Persons</topic><topic>Epidemiology</topic><topic>Heart diseases</topic><topic>Humans</topic><topic>Infectious Diseases</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Netherlands - epidemiology</topic><topic>Oncology</topic><topic>Population</topic><topic>Public Health</topic><topic>Quality-Adjusted Life Years</topic><topic>SARS-CoV-2</topic><topic>Seroepidemiologic Studies</topic><topic>Serology</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Signs and symptoms</topic><topic>Subgroups</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McDonald, Scott A.</creatorcontrib><creatorcontrib>Lagerweij, Giske R.</creatorcontrib><creatorcontrib>de Boer, Pieter</creatorcontrib><creatorcontrib>de Melker, Hester E.</creatorcontrib><creatorcontrib>Pijnacker, Roan</creatorcontrib><creatorcontrib>Mughini Gras, Lapo</creatorcontrib><creatorcontrib>Kretzschmar, Mirjam E.</creatorcontrib><creatorcontrib>den Hartog, Gerco</creatorcontrib><creatorcontrib>van Gageldonk-Lafeber, Arianne B.</creatorcontrib><creatorcontrib>van den f, Susan</creatorcontrib><creatorcontrib>Wallinga, Jacco</creatorcontrib><creatorcontrib>RIVM COVID-19 surveillance, epidemiology team</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of epidemiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McDonald, Scott A.</au><au>Lagerweij, Giske R.</au><au>de Boer, Pieter</au><au>de Melker, Hester E.</au><au>Pijnacker, Roan</au><au>Mughini Gras, Lapo</au><au>Kretzschmar, Mirjam E.</au><au>den Hartog, Gerco</au><au>van Gageldonk-Lafeber, Arianne B.</au><au>van den f, Susan</au><au>Wallinga, Jacco</au><aucorp>RIVM COVID-19 surveillance, epidemiology team</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The estimated disease burden of acute COVID-19 in the Netherlands in 2020, in disability-adjusted life-years</atitle><jtitle>European journal of epidemiology</jtitle><stitle>Eur J Epidemiol</stitle><addtitle>Eur J Epidemiol</addtitle><date>2022-10-01</date><risdate>2022</risdate><volume>37</volume><issue>10</issue><spage>1035</spage><epage>1047</epage><pages>1035-1047</pages><issn>0393-2990</issn><issn>1573-7284</issn><eissn>1573-7284</eissn><abstract>The impact of COVID-19 on population health is recognised as being substantial, yet few studies have attempted to quantify to what extent infection causes mild or moderate symptoms only, requires hospital and/or ICU admission, results in prolonged and chronic illness, or leads to premature death. We aimed to quantify the total disease burden of acute COVID-19 in the Netherlands in 2020 using the disability-adjusted life-years (DALY) measure, and to investigate how burden varies between age-groups and occupations. Using standard methods and diverse data sources (mandatory notifications, population-level seroprevalence, hospital and ICU admissions, registered COVID-19 deaths, and the literature), we estimated years of life lost (YLL), years lived with disability, DALY and DALY per 100,000 population due to COVID-19, excluding post-acute sequelae, stratified by 5-year age-group and occupation category. The total disease burden due to acute COVID-19 was 286,100 (95% CI: 281,700–290,500) DALY, and the per-capita burden was 1640 (95% CI: 1620–1670) DALY/100,000, of which 99.4% consisted of YLL. The per-capita burden increased steeply with age, starting from 60 to 64 years, with relatively little burden estimated for persons under 50 years old. SARS-CoV-2 infection and associated premature mortality was responsible for a considerable direct health burden in the Netherlands, despite extensive public health measures. DALY were much higher than for other high-burden infectious diseases, but lower than estimated for coronary heart disease. These findings are valuable for informing public health decision-makers regarding the expected COVID-19 health burden among population subgroups, and the possible gains from targeted preventative interventions.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>35951278</pmid><doi>10.1007/s10654-022-00895-0</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0003-0788-6011</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0393-2990 |
| ispartof | European journal of epidemiology, 2022-10, Vol.37 (10), p.1035-1047 |
| issn | 0393-2990 1573-7284 1573-7284 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9366822 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Age Cardiology Cardiovascular disease Cardiovascular diseases Complications Coronary artery disease Coronaviruses Cost of Illness COVID-19 Decision making Disability-Adjusted Life Years Disabled Persons Epidemiology Heart diseases Humans Infectious Diseases Medicine Medicine & Public Health Middle Aged Netherlands - epidemiology Oncology Population Public Health Quality-Adjusted Life Years SARS-CoV-2 Seroepidemiologic Studies Serology Severe acute respiratory syndrome coronavirus 2 Signs and symptoms Subgroups Viral diseases |
| title | The estimated disease burden of acute COVID-19 in the Netherlands in 2020, in disability-adjusted life-years |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T22%3A40%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20estimated%20disease%20burden%20of%20acute%20COVID-19%20in%20the%20Netherlands%20in%202020,%20in%20disability-adjusted%20life-years&rft.jtitle=European%20journal%20of%20epidemiology&rft.au=McDonald,%20Scott%20A.&rft.aucorp=RIVM%20COVID-19%20surveillance,%20epidemiology%20team&rft.date=2022-10-01&rft.volume=37&rft.issue=10&rft.spage=1035&rft.epage=1047&rft.pages=1035-1047&rft.issn=0393-2990&rft.eissn=1573-7284&rft_id=info:doi/10.1007/s10654-022-00895-0&rft_dat=%3Cproquest_pubme%3E2701139283%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2731288566&rft_id=info:pmid/35951278&rfr_iscdi=true |